Preliminary Results of Tocilizumab and Interferon α-2β Treatment of SARS-CoV-2.

doi:10.21203/rs.3.rs-98566/v2

Download PDF

Short Report

Preliminary Results of Tocilizumab and Interferon α-2β Treatment of SARS-CoV-2.

https://doi.org/10.21203/rs.3.rs-98566/v2

This work is licensed under a CC BY 4.0 License

Version 2

posted

You are reading this latest preprint version

Seven patients receiving Hydroxychloroquine (HCQ) and Zinc (Zn) for CoVid-19 with PCR positive results were admitted to hospital after failing to improve. Following NCT04349410 protocol and failure to improve with elevated interleukin-6 and ferritin levels, patient’s treatment were changed following measurement of Corona Virus Pneumonia (CVP). Follow up measurements of CVP confirmed improvement with combined intravenous Tocilizumab, Interferon α-2β nebulizer, Atrovent nebulizer and SQ heparin treatment

Infectious Diseases

Nuclear Medicine & Medical Imaging

SARS-CoV-2

CoVid-19

InflammoThrombotic Response (ITR)

FMTVDM

Hydroxychloroquine

Tocilizumab

Interferon α-2β

and NCT04349410